NASDAQ:ARGS - Argos Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.13 -0.01 (-7.14 %)
(As of 11/13/2018 01:51 PM ET)
Previous Close$0.1373
Today's Range$0.13 - $0.14
52-Week Range$0.0751 - $5.80
Volume17,626 shs
Average Volume365,842 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma; and in Phase II clinical trial to treat early stage renal cell carcinoma and muscle invasive bladder cancer. The company also develops AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is based in Durham, North Carolina.

Receive ARGS News and Ratings via Email

Sign-up to receive the latest news and ratings for ARGS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARGS
Previous Symbol
CUSIPN/A
Phone919-287-6300

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees39
Outstanding Shares10,590,000
Market Cap$0.00
OptionableNot Optionable

Argos Therapeutics (NASDAQ:ARGS) Frequently Asked Questions

What is Argos Therapeutics' stock symbol?

Argos Therapeutics trades on the NASDAQ under the ticker symbol "ARGS."

When did Argos Therapeutics' stock split? How did Argos Therapeutics' stock split work?

Shares of Argos Therapeutics reverse split on the morning of Friday, January 19th 2018. The 1-20 reverse split was announced on Thursday, January 18th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 18th 2018. An investor that had 100 shares of Argos Therapeutics stock prior to the reverse split would have 5 shares after the split.

How were Argos Therapeutics' earnings last quarter?

Argos Therapeutics Inc. (NASDAQ:ARGS) announced its quarterly earnings data on Monday, August, 20th. The biopharmaceutical company reported ($0.61) earnings per share for the quarter. The biopharmaceutical company had revenue of $0.05 million for the quarter. View Argos Therapeutics' Earnings History.

When is Argos Therapeutics' next earnings date?

Argos Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, November 15th 2018. View Earnings Estimates for Argos Therapeutics.

Has Argos Therapeutics been receiving favorable news coverage?

News coverage about ARGS stock has trended positive recently, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Argos Therapeutics earned a media sentiment score of 2.4 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the stock's share price in the next few days.

Who are some of Argos Therapeutics' key competitors?

Who are Argos Therapeutics' key executives?

Argos Therapeutics' management team includes the folowing people:
  • Mr. Jeffrey D. Abbey, Pres, CEO & Director (Age 56)
  • Dr. Charles A. Nicolette Ph.D., Chief Scientific Officer and VP of R&D (Age 56)
  • Dr. Richard D. Katz, VP & CFO (Age 54)
  • Ms. Lori R. Harrelson CPA, VP of Fin. & Principal Accounting Officer (Age 49)
  • Mr. John D. Menditto, VP of Corp. Communications and Investor Relations

How do I buy shares of Argos Therapeutics?

Shares of ARGS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Argos Therapeutics' stock price today?

One share of ARGS stock can currently be purchased for approximately $0.13.

What is Argos Therapeutics' official website?

The official website for Argos Therapeutics is http://www.argostherapeutics.com.

How can I contact Argos Therapeutics?

Argos Therapeutics' mailing address is 4233 TECHNOLOGY DR, DURHAM NC, 27704. The biopharmaceutical company can be reached via phone at 919-287-6300.


MarketBeat Community Rating for Argos Therapeutics (NASDAQ ARGS)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  266 (Vote Outperform)
Underperform Votes:  166 (Vote Underperform)
Total Votes:  432
MarketBeat's community ratings are surveys of what our community members think about Argos Therapeutics and other stocks. Vote "Outperform" if you believe ARGS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARGS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/13/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel